CAPR - Capricor Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed price. Currency in USD
1.85
-0.15 (-7.50%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close2.00
Open1.98
Bid1.65 x 5800
Ask1.75 x 100
Day's range1.83 - 1.99
52-week range0.63 - 4.25
Volume499,416
Avg. volume623,424
Market cap47.564M
Beta1.01
PE ratio (TTM)N/A
EPS (TTM)-0.65
Earnings date13 Mar 2018 - 19 Mar 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.60
Trade prices are not sourced from all markets
  • Globe Newswirelast month

    Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies

    Capricor Therapeutics (NASDAQ:CAPR)  announced today that it has added seven new patent applications to its existing Exclusive License Agreements with Cedars-Sinai Medical Center for technologies related to cardiosphere-derived cells (CDCs) and CDC-derived extracellular vesicles, including exosomes. The Exclusive License Agreements with Cedars-Sinai grant Capricor exclusive worldwide rights to commercially develop and market CDCs, which comprise Capricor’s lead investigational cell therapy, CAP-1002, as well as CDC-derived exosomes, which comprise its lead investigational exosome-based therapy candidate, CAP-2003. The new patent applications expand the scope of the Exclusive License Agreements to enable Capricor to develop new therapeutic indications for its cellular and exosome therapies in Duchenne muscular dystrophy, ventricular tachyarrhythmia, cancer and age-related disorders.

  • MarketWatch3 months ago

    Capricor Therapeutics stock rises 18% on FDA clearance for DMD clinical trial

    Capricor Therapeutics Inc. shares rose nearly 18% in extremely heavy Wednesday morning trade after the company said the Food and Drug Administration has cleared its Duchenne muscular dystrophy therapy ...

  • Associated Press3 months ago

    Capricor reports 3Q loss

    The Beverly Hills, California-based company said it had a loss of 12 cents per share. The biotechnology company posted revenue of $313,300 in the period. Its adjusted revenue was $313,000. In the final ...

  • Capricor Therapeutics (CAPR) Looks Good: Stock Adds 13.9% in Session
    Zacks5 months ago

    Capricor Therapeutics (CAPR) Looks Good: Stock Adds 13.9% in Session

    Capricor Therapeutics (CAPR) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes